Loading clinical trials...

Texture and Colour Enhancement Imaging in Improving Detection and Miss Rate of Premalignant Lesions | Clinical Trials | Clareo Health

NOT_YET_RECRUITINGNA

Texture and Colour Enhancement Imaging in Improving Detection and Miss Rate of Premalignant Lesions

Impact of Texture and Color Enhancement Imaging on Detection and Miss Rate of Premalignant Lesions: A Multicentre, Randomized, Tandem Trial

NCT06515977•Changhai Hospital

View on ClinicalTrials.gov

Summary

Texture and Color Enhancement Imaging (TXI) is a newly developed image-enhancing endoscopy technology that has show potential in improving detection of colorectal lesions. This multicenter, randomized, tandem trial is aimed at evaluating whether TXI is superior to WLI endoscopy in terms of diagnosis of premalignant lesions.

Eligibility

Age

45 - 85 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•patients aged 45-85 years and scheduled for screening colonoscopy who provided written informed consent

Exclusion Criteria

•Surveillance, diagnostic or therapeutic colonoscopy
•Patients with an already known or suspected colorectal tumour
•Patients with alarming symptoms and signs, including haematochezia, melena, weight loss or anaemia without specific causes, an abdominal mass and positive digital rectal examination
•Pregnant or lactating women
•Patients with gastrointestinal tract obstruction
•Patients with inflammatory bowel diseases, hereditary CRC syndromes or serrated polyposis syndrome
•Patients with abnormal blood coagulation or taking antiplatelets or anticoagulants within 7 days before colonoscopy
•Patients with failed cecal intubation
•Patients with poor bowel preparation quality that necessitated a second bowel preparation
•Patients with a history of colonic resection

Key Dates

Start Date

August 1, 2024

Primary Completion Date

August 1, 2025

Completion Date

August 1, 2025

Last Updated

July 23, 2024

Enrollment

2,964

ESTIMATED participants

Conditions

AdenomaSessile Serrated Adenoma

Interventions

TXI (Group A)

PROCEDURE

TXI followed by WLI (Group B)

PROCEDURE

WLI (Group C)

PROCEDURE

WLI followed by TXI (Group D)

PROCEDURE

Contacts

Zhaoshen Li, MD

CONTACT

86-021-31161365 li.zhaoshen@hotmail.com

Yu Bai, MD

CONTACT

86-021-31161335 baiyu1998@hotmail.com

DDAVP for Pituitary Adenoma

NCT04569591

Cushing's DiseasePituitary Adenoma

View study

RECRUITINGPHASE3

Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis

NCT06950385

Familial Adenomatous Polyposis (FAP)

View study

RECRUITING

Familial Investigations of Childhood Cancer Predisposition

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 23, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Texture and Colour Enhancement Imaging in Improving Detection and Miss Rate of Premalignant Lesions

Inclusion Criteria

Exclusion Criteria

DDAVP for Pituitary Adenoma

Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis

Familial Investigations of Childhood Cancer Predisposition

Trial of Exercise Therapy in Familial Adenomatous Polyp (FAP)

PARADIGM - En Bloc Trial With the EndoQuest Endoluminal Surgical (ELS) System

A Phase 2 Open-label Single-arm Trial of JAK1 Inhibitor for the Treatment of Large Inflammatory Hepatocellular Adenomas